Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

To compare drug survival of ixekizumab to other IL‐17 inhibitors (IL‐17i) and TNF inhibitors (TNFi) among patients with psoriasis (PsO) in a real‐world setting. Participants included adult PsO patients enrolled in the Corrona Psoriasis Registry who initiated ixekizumab, TNFi, or other IL‐17i between...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockshin, Benjamin, Cronin, Angel, Harrison, Ryan W., McLean, Robert R., Anatale‐Tardiff, Laura, Burge, Russel, Zhu, Baojin, Malatestinic, William N., Atiya, Bilal, Murage, Mwangi J., Gallo, Gaia, Strober, Bruce, Van Voorhees, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047872/
https://www.ncbi.nlm.nih.gov/pubmed/33491259
http://dx.doi.org/10.1111/dth.14808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047872/
https://www.ncbi.nlm.nih.gov/pubmed/33491259
http://dx.doi.org/10.1111/dth.14808

Ejemplares similares